Tim Fenske

Anyone who has worked with me on inpatient service knows that the Anion Gap is one of my favorite lab tests. So many things it can help diagnose… So imagine how happy I was to meet Dr Emmett, widely credited with popularizing the use of the AG in modern medicine!

@RoshanaMN @EricTopol @AnnalsofIM @ACPIMPhysicians 100% agree. I have worked with numerous amazing NPs and PAs who I would trust to care for me or my family. However we physicians did not go to “provider school”. The training is not the same and the roles are not the same.

@EricTopol @AnnalsofIM @ACPIMPhysicians I’ve always thought this was odd (when I was in the states) It removes the trust & human connection, it allows other healthcare professionals to pass themselves off as physicians without the patient realising, it’s a soulless term

"The term [provider] should not be used to describe physicians, nor should physicians use it to describe themselves, their team members, or their trainees." acpjournals.org/doi/10.7326/AN… @AnnalsofIM @ACPIMPhysicians

@Papa_Heme This would be a great debate topic at a meeting. I’m not an ALL guru but the data I’ve seen for Ph-like ALL looks pretty dismal without transplant. I do question whether we should be transplanting all clonoSEQ (+) pts esp when 1-2/ million, then zero after Blin

In my opinion, regardless of initial risk (Ph like etc) MRD negative patients with B-ALL who will receive blinatumomab should not go to allogeneic transplant

@adamcifu Interesting take but not particularly useful for those of us who have been dealing with tinnitis for years. For me the tones are not pleasant

Possibly the best 3 minutes you’ll ever hear about tinnitus. overcast.fm/+ABSrfk1c1ns

RFK jr created a whole video to “debunk” this 100% correct chart. Our HHS Secretary.

@honeymoon250 Squash, Lacrosse, tennis, foursquare, ping pong

This is hard

@AmandaYerrick Hope you have a great holiday and get a little down time too! Nice catching up at ASH!

Merry Christmas & Happy Holidays from the corporate HQ in Indy! It has been an incredibly busy & rewarding year for me professionally. I hope everyone takes some time to relax and reflect as we head into 2026.

@Matt_Pinner 13

I've been to 4,how many have you been to?

Amazing show - got to see Paul McCartney with my dad 😊

@Papa_Heme Love our doctor’s lounge too. And the free food for MDs and APPs in the cafeteria !

I was never burned out at my old job. Just doctor lounge deficient. Today’s lunch Spanish rice with grilled flank stake, balsamic glazed portabellas, and cheesecake with chocolate drizzle. Paired with Perrier sparkling water.

RW pola outcomes by Hans COO @CCR_AACR - 740 pts, 59% R/R - R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC - 1L: no diff in outcomes Hans useful in choosing pola in R/R LBCL. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm aacrjournals.org/clincancerres/…

@JohnCleese .

.

@VincentRK For sure, tough to give older pts. I was thinking more for the under 65-70 group who are rapidly progressing and you’re trying to open up a brief window to benefit from CART

@timfenske Yes. Good old VDT PACE. It’s rocky course though and not possible in elderly patients. After age 70 VDT PACE can be life threatening on its own.

I am scared of using CART or bispecifics in myeloma with large volume disease: CRS, neurotoxicity, HLH, risk of death, and all kinds of complications are much higher. I’d rather control myeloma and get it to low volume before using these immunotherapy treatments. This is why we need more new classes of myeloma drugs. CARTs and bispecifics are great treatments and can prolong life by a long time if we use them correctly. But if say DaraVRd and KPd don’t work you are quickly out of good options to control myeloma, and then we are forced to sometimes take the risk with bispecifics and CART inspite of large volume disease. So while we have a lot of treatment options in myeloma, that’s context dependant. Many of the options are in similar drug classes and don’t really work well if DaraVRd and KPd don’t. For biologically aggressive refractory myeloma we have a ways to go. In this regard, I feel drugs like belantamab if approved can offer one way of reducing tumor burden to enable use of CART and bispecifics. Of course belantamab alone is not going to help either. We need a lot more new drugs with new mechanisms of action, if not for anything else but to debulk so we can safely use bispecifics, trispecifics, and CART.

@sghmd @statnews @angRchen Really great thread @sghmd ! Should be required reading for all heme/onc fellows (and apparently journalists writing about transplant and cell therapy!)

I'm concerned that the recent @statnews piece re: decline of #BMT by @angRchen could be misleading to the public. Adding some context for consideration in the thread 🧵below: statnews.com/2024/12/24/bon…

@Bethfaiman Congrats Marcelo! they are lucky to have you 👍

The *A* team! So honored to have Drs. Pasquini, Brunstein, and Bezerra joining our team! 👏👏

Michelangelo’s Pietà recreated with drones over St Peter’s at the Vatican last night

CONGRESS | #SOHO2025 | PRESENTATION Timothy S. Fenske @timfenske, Sarah Cannon Cancer Institute, discusses methods and applications for MRD in front-line and R/R #MantleCellLymphoma settings, including prognostication after treatment, a clinical trial endpoint, surveillance tool, and a trigger for pre-emptive therapy. Follow our live feed for more updates: loom.ly/rBZZxmc #Lymphoma #lymsm #MedicalCongress

Ide-cel and Cilta-cel for PCL. N=34, median PFS/OS with ide-cel: 6/9 months; median PFS/OS with cilta cel: 19/>23 months #bmtsm #mmsm @GliceidaGalarzaMD @BloodPortfolio ashpublications.org/bloodadvances/…

Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.